Antibiotic use in pregnancy and lactation: What is and is not known about teratogenic and toxic risks

Obstetrics and Gynecology

Volumn 107, Issue 5, 2006, Pages 1120-1138

  Nahum, Gerard G ^a   Uhl, Kathleen ^b   Kennedy, Dianne L ^b  

^a Box 2184   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CHLORAMPHENICOL DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; LEVOFLOXACIN; PENICILLIN G; PENICILLIN V POTASSIUM; QUININE; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BONE MARROW TOXICITY; BRADYCARDIA; BREAST FEEDING; CARDIOVASCULAR MALFORMATION; CLEFT LIP PALATE; CONGENITAL MALFORMATION; DEVELOPMENTAL DISORDER; DRUG CLEARANCE; DRUG EXCRETION; DRUG INDICATION; DRUG METABOLISM; DRUG MILK LEVEL; DRUG MONITORING; DRUG SAFETY; ENAMEL HYPOPLASIA; FETOTOXICITY; FOOD AND DRUG ADMINISTRATION; HEARING DISORDER; HUMAN; HYPOSPADIAS; LACTATION; LIVER NECROSIS; MUSCULOSKELETAL DISEASE; NECROTIZING ENTEROCOLITIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PLACENTAL TRANSFER; POLYDACTYLY; PREGNANCY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; RISK ASSESSMENT; SPINA BIFIDA; SPONTANEOUS ABORTION; TERATOGENICITY; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BREAST FEEDING; FEMALE; HUMANS; LACTATION; MATERNAL-FETAL EXCHANGE; PREGNANCY;

EID: 33646814764     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000216197.26783.b5     Document Type: Review

References (125)

1. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398-407.
2. Ventura SJ, Abma JC, Mosher WD, Henshaw S. Estimated pregnancy rates for the United States, 1990-2000: an update. Natl Vital Stat Rep 2004;52:1-9.
3. Stika CS, Frederiksen MC. Drug therapy in pregnant and nursing women. In: Atkinson AJ, editor. Principles of clinical pharmacology. San Diego (CA): Academic Press, 2001.
4. CDC. Emergency preparedness and response. Agents, diseases, & other threats: bioterrorism agents/diseases, by category. Available at: www.bt.cdc.gov/agent/agentlist-category.asp. Retrieved March 2, 2006.
5. Wasz-Hockert O, Nummi S, Vuopala S, Jarvinen PA. Transplacental passage of azidocillin, ampicillin, and penicillin G during early and late pregnancy. Acta Paediatr Scand Suppl 1970;206:109-10.
6. Philipson A. Pharmacokinetics of ampicillin during pregnancy. J Infect Dis 1977;136:370-6.
7. Bray RE, Boe RW, Johnson WL. Transfer of ampicillin into fetus and amniotic fluid from maternal plasma in late pregnancy. Am J Obstet Gynecol 1966;96:938-42.
8. Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. Acta Paediatr Scand 1981;70:285-8.
9. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
10. Nau H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. Dev Pharmacol Ther 1987;10:174-98.
11. Heikkila AM, Erkkola RU. The need for adjustment of dosage regimen of penicillin V during pregnancy. Obstet Gynecol 1993;81:919-21.
12. Scott WC, Warner RF. Placental transfer of chloramphenicol (chloromycetin). J Am Med Assoc 1950;142:1331-2.
13. Havelka J, Hejzlar M, Popov V, Viktorinova D, Prochazka J. Excretion of chloramphenicol in human milk. Chemotherapy 1968;13:204-11.
14. Smadel JE, Woodward TE, Ley HL, Lewthwaite R. Chloramphenicol (chloromycetin) in the treatment of Tsutsugamushi disease (scrub typhus). J Clin Invest 1949;28:1196-215.
15. Vorherr H. Drug excretion in breast milk. Postgrad Med 1974;56:97-104.
16. Bennet PN, editor. The WHO Working Group. Drugs and human lactation: a guide to the content and consequences of drugs, micronutrients, radiopharmaceuticals, and environmental and occupational chemicals in human milk. New York (NY): Elsevier, 1988.
17. Giamarellou H, Kolokythas E, Petrikkos G, Gazis J, Aravantinos D, Sfikakis P. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med 1989;87:49S-51S.
18. Chung AM, Reed MD, Blumer JL. Antibiotics and breastfeeding: a critical review of the literature. Pediatr Drugs 2002;4:817-37.
19. von Rosenstiel N, Adam D. Quinolone antibacterials: An update of their pharmacology and therapeutic use. Drugs 1994;47:872-901.
20. Weinstein AJ, Gibbs RS, Gallagher M. Placental transfer of clindamycin and gentamicin in term pregnancy. Am J Obstet Gynecol 1976;124:688-91.
21. Philipson A, Sabath LD, Charles D. Transplacental passage of erythromycin and clindamycin. N Engl J Med 1973;288:1219-21.
22. Rothman KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol 1988;19:431-42.
23. Soper DE. Clindamycin. Obstet Gynecol Clin North Am 1992;19:483-96.
24. Philipson A, Sabath LD, Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. Clin Pharmacol Ther 1976;19:68-77.
25. Morganti G, Ceccarelli G, Ciaffi G. Comparative concentrations of a tetracycline antibiotic in serum and maternal milk [article in multiple languages]. Antibiotica 1968;6:216-23.
26. Yoshioka H, Monma T, Matsuda S. Placental transfer of gentamicin. J Pediatr 1972;80:121-3.
27. Regev RH, Litmanowitz I, Arnon S, Shiff J, Dolfin T. Gentamicin serum concentrations in neonates born to gentamicin-treated mothers. Pediatr Infect Dis J 2000;19:890-1.
28. Kauffman RE, Morris JA, Azarnoff DL. Placental transfer and fetal urinary excretion of gentamicin during constant rate maternal infusion. Pediatr Res 1975;9:104-7.
29. Celiloglu M, Celiker S, Guven H, Tuncok Y, Demir N, Erten O. Gentamicin excretion and uptake from breast milk by nursing infants. Obstet Gynecol 1994;84:263-5.
30. Chow AW, Jewesson PJ. Pharmacokinetics and safety of antimicrobial agents during pregnancy. Rev Infect Dis 1985;7:287-313.
31. Lazebnik N, Noy S, Lazebnik R, Hezroni Y, Amoday I, Aviram A. Gentamicin serum half-life: a comparison between pregnant and non-pregnant women. Postgrad Med J 1985;61:979-81.
32. McNeeley SG Jr, Beitel R, Lee M, Moise C, Dilts PV Jr. Delayed gentamicin elimination in patients with severe pre-eclampsia. Am J Obstet Gynecol 1985;153:793-6.
33. Hutter A, Parks J. The transmission of penicillin through the placenta: a preliminary report. Am J Obstet Gynecol 1945;49:663-5.
34. Woltz J, Zintel H. The transmission of penicillin to the previable fetus. JAMA 1946;131:969-70.
35. Matheson I, Samseth M, Loberg R, Faegri A, Prentice A. Milk transfer of phenoxy-methylpenicillin during puerperal mastitis. Br J Clin Pharmacol 1988;25:33-40.
36. Greene H, Burkhart B, Hobby GL. Excretion of penicillin in human milk following parturition. Am J Obstet Gynecol 1946;51:732-3.
37. Holdiness MR. Teratology of the antituberculosis drugs. Early Hum Dev 1987;15:61-74.
38. Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev 1981;12:159-218.
39. Rocker I. Rifampicin in early pregnancy. Lancet 1977;2:48.
40. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984;9:511-44.
41. Snider DE Jr, Powell KE. Should women taking antituberculosis drugs breast-feed? Arch Intern Med 1984;144:589-90.
42. Reyes MP, Ostrea EM, Cabinian AE, Schmitt C, Rintelmann W. Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am J Obstet Gynecol 1989;161:977-81.
43. Bourget P, Fernandez H, Delouis C, Ribou F. Transplacental passage of vancomycin during the second trimester of pregnancy. Obstet Gynecol 1991;78:908-11.
44. Friedman JM, Polifka JE. Teratogenic effects of drugs: a resource for clinicians (TERIS). Baltimore (MD): Johns Hopkins University Press; 2000.
45. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study. Eur J Obstet Gynecol Reprod Biol 2001;97:188-92.
46. Jepsen P, Skriver MV, Floyd A, Lipworth L, Schonheyder HC, Sorensen HT. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark. Br J Clin Pharmacol 2003;55:216-21.
47. Colley DP, Kay J, Gibson GT. Amoxycillin and ampicillin: a study of their use in pregnancy. Aust J Pharm 1983;64:107-11.
48. Cavenee MR, Farris JR, Spalding TR, Barnes DL, Castaneda YS, Wendel GD Jr. Treatment of gonorrhea in pregnancy. Obstet Gynecol 1993;81:33-8.
49. Almeida L, Schmauch A, Bergstrom S. A randomised study on the impact of peroral amoxicillin in women with prelabour rupture of membranes preterm. Gynecol Obstet Invest 1996;41:82-4.
50. Lovett SM, Weiss JD, Diogo MJ, Williams PT, Garite TJ. A prospective, double-blind, randomized, controlled clinical trial of ampicillin-sulbactam for preterm premature rupture of membranes in women receiving antenatal cortucisteroid therapy. Am J Obstet Gynecol 1997;176:1030-8.
51. Mercer BM, Miodovnik M, Thurmau GR, Goldenberg RL, Das AF, Ramsey RD, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: a randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 1997;278:989-95.
52. Kenyon SL, Taylor DJ, Tarnow-Mordi WO. ORACLE - antibiotics for preterm prelabour rupture of the membranes: short-term and long-term outcomes. Acta Paediatr Suppl 2002;91:12-5.
53. Kenyon SL, Taylor DJ, Tarnow-Mordi W; ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group. Lancet 2001;357:979-88.
54. Abou-Tarboush FM. Teratogenic and toxic effects of Hiconcil (amoxicillin) on mouse fetuses. Arab Gulf J Sci Res 1994;12:133-40.
55. Hirakawa T, Suzuki T, Sano Y, et al. Reproduction studies in rats. Chemotherapy 1983;31:263-72.
56. James PA, Hardy TL, Koshima Y. Reproduction studies of BRL 25000. Teratology studies in the pig. Chemotherapy 1983;31:274-9.
57. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of oral chloramphenicol treatment during pregnancy. Eur J Epidemiol 2000;16:323-7.
58. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group; 1977.
59. Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant: a physiologic explanation of its toxicity when given in excessive doses. Engl J Med 1960;262:787-94.
60. Courtney KD, Valerio DA. Teratology in the Macaca mulatta. Teratology 1968;1:163-72.
61. Fritz H, Hess R. The effect of chloramphenicol on the prenatal development of rats, mice, and rabbits. Toxicol Appl Pharmacol 1971;19:667-74.
62. Prochazka J, Simkova V, Havelka J, Hejzlar M, Viklicky J, Kargerova A, et al. On the problem of the penetration of the placenta by chloramphenicol. Preliminary report [in Czech]. Cesk Pediatr 1964;19:311-4.
63. Takaya M. Teratogenic effects of antibiotics. J Osaka City Med Cent 1965;14:107-15.
64. Siddiqui MA, Janjua MZ. Effect of prenatal doxycycline administration on skeletal differentiation in long bones of Albino rat. J Pak Med Assoc 2002;52:211-4.
65. Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998;42:1336-9.
66. Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. Am J Med 1991;91:153S-161S.
67. Daniscovicova A, Brezina M, Belan S, Kayserova H, Kaiserova E, Hruskovic I, et al. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy: a multicenter survey. Chemotherapy 1994;40:209-14.
68. Koul P, Wani J, Wahid A. Ciprofloxacin for multiresistant enteric fever in pregnancy. Lancet 1995;346:307-8.
69. Schluter G. Ciprofloxacin: toxicologic evaluation of additional safety data. Am J Med 1989;87:37S-9S.
70. Centers for Disease Control and Prevention (CDC). Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep 2001;50:960.
71. Rosa F. 1993. Cited in: Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2002. p. 112.
72. McGready R, Cho T, Samuel, Villegas L, Brockman A, van Vugt M, et al. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 2001;95:651-6.
73. McCormack WM, Rosner B, Lee YH, Munoz A, Charles D, Kass EH. Effect on birth weight of erythromycin treatment of pregnant women. Obstet Gynecol 1987;69:202-7.
74. Ou M, Pang CC, Chen FM, Su CH, Ou D. Antibiotic treatment for threatened abortion during the early first trimester in women with previous spontaneous abortion. Acta Obstet Gynecol Scand 2001;80:753-6.
75. Rothman KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol 1988;19:431-42.
76. Mann CF. Clindamycin and breast-feeding. Pediatrics 1980;66:1030-1.
77. Gray JE, Weaver RN, Bollert JA, Feenstra ES. The oral toxicity of clindamycin in laboratory animals. Toxicol Appl Pharmacol 1972;21:516-31.
78. Bollert JA, Gray JE, Highstrete JD, Moran J, Purmalis BP, Weaver RN. Teratogenicity and neonatal toxicity of clindamycin 2-phosphate in laboratory animals. Toxicol Appl Pharmacol 1974;27:322-9.
79. Czeizel AE, Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997;89:524-8.
80. Horne HW Jr, Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. Int J Fertil 1980;25:315-7.
81. Schultz JC, Adamson JS Jr, Workman WW, Norman TD. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 1963;269:999-1004.
82. Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF. Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 1981;26:135-41.
83. Kunelis CT, Peters JL, Edmondson HA. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med 1965;38:359-77.
84. Genot MT, Golan HP, Porter PJ, Kass EH. Effect of administration of tetracycline in pregnancy on the primary dentition of the offspring. J Oral Med 1970;25:75-9.
85. Rebich T, Kumar J, Brustman B. Dental caries and tetracycline-stained dentition in an American Indian population. J Dent Res 1985;64:462-4.
86. Cohlan SQ, Bevelander G, Tiamsic T. Growth inhibition of prematures receiving tetracycline. Am J Dis Child 1963;105:453-61.
87. Bastianini L, Felisati D. Studies on gravidic and fetal toxicity of alpha-6-deoxy-5-oxytetracycline (doxycycline) in mouse and rabbit [article in multiple laguages]. Antibiotica 1970;8:161-78.
88. Cahen RL, Fave A. Absence of teratogenic effect of 6-alpha-deoxy-5 oxytetracycline. Proc Fed Am Soc Exp Biol 1972;31:238.
89. Delahunt C, Jacobs R, Stebbins R, Reiser N. Toxicology of vibramycin. Toxic Appl Pharm 1967;10:402.
90. Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, et al. Pregnancy outcome after prenatal quinolone exposure. Evaluation of case registry of European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 1996;69:83-9.
91. Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A teratological study of aminoglycoside antibiotic treatment during pregnancy. Scand J Infect Dis 2000;32:309-13.
92. Wing DA, Hendershott CM, Debuque L, Millar LK. A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy. Obstet Gynecol 1998;92:249-53.
93. Suarez V, Olson G, Saade G, Locksmith G, Hankins G. The effect of in utero exposure to gentamicin on newborn oto-acoustic emissions. Am J Obstet Gynecol 2001;184:S52.
94. Hulton SA, Kaplan BS. Renal dysplasia associated with in utero exposure to gentamicin and corticosteroids. Am J Med Genet 1995;58:91-3.
95. Nishio A, Ryo S, Miyao N. Effects of gentamicin, exotoxin, and their combination on pregnant mice. Bull Fac Agric Kagoshima Univ 1987;37:129-36.
96. Deguine O, Chappert C, Fonta C, Imbert M. Prenatal lesioning of vestibular organ by aminoglycosides. Neuroreport 1996;7:2435-8.
97. Gilbert T, Lelievre-Pegorier M, Merlet-Benichou C. Immediate and long-term renal effects of fetal exposure to gentamicin. Pediatr Nephrol 1990;4:445-50.
98. Watanabe T, Fujikawa K, Harada S, Ohura K, Sasaki T, Takayama S. Reproductive toxicity of the new quinolone antibacterial agent levofloxacin in rats and rabbits. Arzneimittelforschung 1992;43:374-7.
99. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratological study of three parenteral penicillins G. Congenital Anomalies 1999;39:117-26.
100. Kullander S, Kallen B. A prospective study of drugs and pregnancy. 4. Miscellaneous drugs. Acta Obstet Gynecol Scand 1976;55:287-95.
101. Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology 1998;57:1-7.
102. Czeizel AE, Rockenbauer M, Olsen J. Use of antibiotics during pregnancy. Eur J Obstet Gynecol Reprod Biol 1998;81:1-8.
103. Boucher D, Delost P. Postnatal development of the descendants from mothers treated with penicillin during pregnancy in mice [in French]. C R Seances Soc Biol Fil 1964;158:528-32.
104. Brown DM, Harper KH, Palmer AK, Tesh SA. Effect of antibiotics upon pregnancy in the rabbit. Toxicol Appl Pharmacol 1968;12:295.
105. Dencker BB, Larson H, Jensen ES, Schonheyder HC, Nielsen GL, Sorensen HT. Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero. Clin Microbiol Infect 2002;8:196-201.
106. Czeizel AE, Rockenbauer M, Sáorensen HT, Olsen J. Oral phenoxymethyl-penicillin treatment during pregnancy: results of a population-based Hungarian case-control study. Arch Gynecol Obstet 2000;263:178-81.
107. Snider DE Jr, Layde PM, Johnson MW, Lyle MA. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980;122:65-79.
108. Stevenson AC, Dudgeon MY, McClure HI. Observations on the results of pregnancies in women resident in Belfast. II. Abortions, hydatidiform moles and ectopic pregnancies. Ann Hum Genet 1959;23:395-414.
109. Steen JS, Stainton-Ellis DM. Rifampicin in pregnancy. Lancet 1977;2:604-5.
110. Bhargava P, Kuldeep CM, Mathur NK. Antileprosy drugs, pregnancy and fetal outcome. Int J Lepr Other Mycobact Dis 1996;64:457-8.
111. Khan MY, Mah MW, Memish ZA. Brucellosis in pregnant women. Clin Infect Dis 2001;32:1172-7.
112. Stratford BF. Observations on laboratory rodents treated with "rifamide" during pregnancy. Med J Aust 1966;1:10-2.
113. Dezulian V, Serralunga MG, Maffii G. Pharmacology and toxicology of rifamide. Toxicol Appl Pharmacol 1966;8:126-37.
114. MacCulloch D. Vancomycin in pregnancy. N Z Med J 1981;93:93-4.
115. Hill LM. Fetal distress secondary to vancomycin-induced maternal hypotension. Am J Obstet Gynecol 1985;153:74-5.
116. Byrd RA, Gries CL, Buening MK. Developmental toxicology studies of vancomycin hydrochloride administered intravenously to rats and rabbits. Fundam Appl Toxicol 1994;23:590-7.
117. USP DI: vancomycin. In: USP DI (USP Dispensing Information) Volume I. Drug information for the health care professional, 21st ed. Englewood (CO): Micromedex Thomson Healthcare; 2001. p. 2963.
118. Centers for Disease Control and Prevention (CDC). Update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 2001;50:1014-6.
119. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999;341:815-26.
120. Committee on Obstetric Practice. Management of asymptomatic pregnant or lactating women exposed to anthrax. Int J Gynecol Obstet 2002;77:293-5.
121. Centers for Disease Control and Prevention (CDC). Division of vector-borne infectious diseases: information on plague. 2003.Available at: www.cdc.gov/ncidod/dvbid/plague/info.htm. Retrieved November 12, 2005.
122. Centers for Disease Control and Prevention (CDC). Tularemia-United States, 1990-2000. MMWR 2002;51:181-4.
123. Centers for Disease Control and Prevention (CDC). Division of Viral and Rickettsial Zoonoses Branch: Q fever., 2003. Available at: www.cdc.gov/ncidod/ dvrd/qfever. Retrieved November 12, 2005.
124. New Drug and Biological Drug Products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. 67 Federal Register 37988 (2002) (codified at 21 CFR § Parts 314 and 601).
125. Project BioShield Act of 2004, Pub. L. No. 108-276, 118 Stat. 835 (July 21, 2004).